Standard BioTools
LAB
138 hedge funds and large institutions have $269M invested in Standard BioTools in 2021 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 43 increasing their positions, 41 reducing their positions, and 34 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 41
5% less funds holding
Funds holding: 145 → 138 (-7)
8.48% less ownership
Funds ownership: 88.1% → 79.63% (-8.5%)
21% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 34
25% less call options, than puts
Call options by funds: $4.53M | Put options by funds: $6.01M
31% less capital invested
Capital invested by funds: $391M → $269M (-$123M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
ICM
Indaba Capital Management
San Francisco,
California
|
+$10.5M |
| 2 |
NIM
Needham Investment Management
New York
|
+$6.33M |
| 3 |
CPA
Cowen Prime Advisors
New York
|
+$5.4M |
| 4 |
SC
Samjo Capital
New York
|
+$4.48M |
| 5 |
O
OrbiMed
New York
|
+$3.88M |
Top Sellers
| 1 |
AI
Atom Investors
Austin,
Texas
|
-$17.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.2M |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$9.27M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$7.67M |
| 5 |
GCM
Glenview Capital Management
New York
|
-$4.86M |
LAB Hedge Fund Activity: Q1 2021 in Review
138 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q1 2021, worth a combined $269M — down 31% from $391M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of LAB and 27 opened new positions — a net loss of 7 holders — while 41 trimmed existing stakes and 43 added.
The largest buyer was Indaba Capital Management, adding an estimated $10.5M. The largest seller was Atom Investors, exiting entirely with an estimated $17.5M sold.
- 138 institutional investors held Standard BioTools (LAB) as of Q1 2021, down from 145 in Q4 2020.
- Funds reported $269M of Standard BioTools stock for Q1 2021, down 31% quarter-over-quarter.
- 27 funds opened new Standard BioTools positions in Q1 2021 and 34 closed out, a net change of -7 holders.
- The largest Standard BioTools buyer in Q1 2021 was Indaba Capital Management, an estimated $10.5M added.
- The largest Standard BioTools seller in Q1 2021 was Atom Investors, an estimated $17.5M sold.
Based on aggregated 13F filings for Q1 2021.